Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. The long-term goal of our proposed project is to reduce the population burden of CRC by providing the information needed to address key policy questions and prioritize future research. To accomplish this goal we will use our population- based microsimulation models to: 1) Inform emerging issues in health policy across the CRC-control spectrum; 2) Guide CRC research priorities and study design using a value of information (VOI) framework; and 3) Engage stakeholders, train modelers, and promote model transparency to ensure high-quality evaluation of CRC control measures, now and in the future. Our team will fill critical gaps in knowledge, enabling decision makers to act. Important gaps in knowledge include the impact of failures in screening and treatment processes on CRC burden; the potential to safely reduce screening and surveillance intensity among some patients based on currently available tools for risk-stratification; the potential benefit of new targeted screening approaches based on patient-level information (i.e., precision medicine); and the importance of clinical management of diminutive polyps. The three participating modeling groups are well-positioned to carry out this work, bringing a wealth of experience, expertise, and insight to issues related to microsimulation modeling of CRC, and have a proven track record of collaborating and disseminating our work to health policy decision makers.

Public Health Relevance

Despite large increases in screening in the past two decades, colorectal cancer remains the second leading cause of cancer death in the United States. Our research has shown that 60% of these deaths could be prevented by better use of available screening interventions. In this proposal, we use microsimulation modeling to help prioritize interventions and future research to further reduce the burden of colorectal cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA199335-05
Application #
9772375
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Scott, Susan M
Project Start
2015-09-10
Project End
2020-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Alarid-Escudero, Fernando; MacLehose, Richard F; Peralta, Yadira et al. (2018) Nonidentifiability in Model Calibration and Implications for Medical Decision Making. Med Decis Making 38:810-821
Gini, Andrea; Zauber, Ann G; Cenin, Dayna R et al. (2018) Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gastroenterology 154:556-567.e18
Meester, Reinier G S; Peterse, Elisabeth F P; Knudsen, Amy B et al. (2018) Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. Cancer 124:2974-2985
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Lansdorp-Vogelaar, Iris; Goede, S Lucas; Bosch, Linda J W et al. (2018) Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. Clin Gastroenterol Hepatol 16:504-512.e11
Peterse, Elisabeth F P; Meester, Reinier G S; Siegel, Rebecca L et al. (2018) The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer 124:2964-2973
Naber, Steffie K; Kuntz, Karen M; Henrikson, Nora B et al. (2018) Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. Gastroenterology 154:105-116.e20
Peterse, Elisabeth F P; Meester, Reinier G S; Gini, Andrea et al. (2017) Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries. Health Aff (Millwood) 36:2151-2159
Goede, S Lucas; Rabeneck, Linda; van Ballegooijen, Marjolein et al. (2017) Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLoS One 12:e0172864
Rutter, Carolyn M; Knudsen, Amy B; Marsh, Tracey L et al. (2016) Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications. Med Decis Making 36:604-14

Showing the most recent 10 out of 15 publications